NCT03356639View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 22, 2018

Primary Completion Date

May 30, 2018

Study Completion Date

May 30, 2018

Conditions

Schizophrenia

Interventions

DRUG

ASP6981

Oral

DRUG

Placebo

Oral

Trial Locations (2)

78754

Community Clinical Research, Austin

91206

Cctmg/Parexel, Glendale

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03356639 - A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter